Relationship between atorvastatin dose and the harm caused by torcetrapib

by Philip J. Barter, Kerry-Anne Rye, Mohan S. Beltangady, William C. Ports, William T. Duggan, S. Matthijs Boekholdt, David A. DeMicco, John J.P. Kastelein, Charles L. Shear
Published 2012-11-01

Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.

by Benoit J Arsenault, Philip Barter, David A DeMicco, Weihang Bao, Gregory M Preston, John C LaRosa, Scott M Grundy, Prakash Deedwania, Heiner Greten, Nanette K Wenger, James Shepherd, David D Waters, John J P Kastelein, Treating to New Targets (TNT) Investigators
Published 2014-01-01

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

by Harshal A. Deshmukh, Helen M. Colhoun, Toby Johnson, Paul M. McKeigue, D. John Betteridge, Paul N. Durrington, John H. Fuller, Shona Livingstone, Valentine Charlton-Menys, Andrew Neil, Neil Poulter, Peter Sever, Denis C. Shields, Alice V. Stanton, Aurobindo Chatterjee, Craig Hyde, Roberto A. Calle, David A. DeMicco, Stella Trompet, Iris Postmus, Ian Ford, J. Wouter Jukema, Mark Caulfield, Graham A. Hitman
Published 2012-05-01